OR
Cardiology - Hypertension
Explore the contemporary role of nebivolol in hypertension management, focusing on its high β1 selectivity and nitric oxide-mediated vasodilatory properties. This educational infographic reviews randomized evidence demonstrating effective blood pressure reduction and emerging 2026 real-world data comparing nebivolol with other β-blockers. It also explains why β-blockers are not routine first-line therapy for uncomplicated hypertension and highlights patient-specific considerations when β-blockade is clinically indicated, including the important distinction between nebivolol and evidence-based β-blockers for HFrEF.
0 Likes
0 Comments
Stay at the forefront of hypertension management by joining our HTN Updates Forum. Access expert-curated infographics, real-world case reports, engaging eCMEs, and insightful videos that translate the scientific evidence into practical clinical knowledge. Designed exclusively for healthcare professionals, the forum delivers the latest evidence, guideline updates, and practical clinical insights to support confident, evidence-based treatment decisions. Follow the forum to stay informed with emerging research and expert perspectives in hypertension care.
© 2026 i-rhythm, All Rights Reserved. MSN i-Rhythm does not provide medical advice, diagnosis or treatment.
For unrestricted access to content and a seamless experience,
Complete your profile to help us deliver a more personalized experience.